Recent Company News

• 08:54 AM ET Jun 09, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:31 PM ET Jun 09, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 10:18 PM ET Jun 06, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 07:34 PM ET Jun 05, 2025
  

  Takeda Pharmaceutical objects to ISS recommendation that shareholders vote against re-election of CEO Christophe Weber to the board (¥4274.0000, 0)

• 07:54 PM ET Jun 04, 2025
  

  Hutchmed and Innovent Biologics notes NDA acceptance by NMPA for fruquintinib combination with sintilimab for treatment of advanced renal cell carcinoma (HK$23.70, 0.00)

• 10:14 AM ET Jun 03, 2025
  

  European Commission approves ADCETRIS for the treatment of adult patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in combination with ECADD (¥4288.0000, 0)

• 09:02 AM ET Jun 03, 2025
  

  FDA discloses paragraph IV patent certifications, including Supernus' QELBREE as previously disclosed by the sponsor

• 08:13 AM ET Jun 01, 2025
  

  Takeda Pharmaceutical, Protagonist Therapeutics's phase III VERIFY study of rusfertide meets primary and all key secondary endpoints (¥4314.0000, 0)

• 08:04 AM ET May 27, 2025
  

  XOMA Royalty acquires mezagitamab royalty and milestone rights held by BioInvent (BINV.SS) ($24.85, 0.00)